Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy

被引：41

作者：

Cai, Hongzhen ^{[1
,2
]}

Li, Man ^{[1
,2
]}

Deng, Ruiyi ^{[1
,2
]}

Wang, Mopei ^{[3
]}

Shi, Yanyan ^{[1
]}

机构：

[1] Peking Univ Third Hosp, Res Ctr Clin Epidemiol, Beijing 100191, Peoples R China

[2] Peking Univ, Hlth Sci Ctr, Beijing 100191, Peoples R China

[3] Peking Univ Third Hosp, Dept Med Oncol & Radiat Sickness, Beijing 100191, Peoples R China

来源：

BIOMARKER RESEARCH | 2022年 / 10卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Gastric cancer; Immunotherapy; Anti-PD-1; Biomarker; Checkpoint inhibitor; GASTROESOPHAGEAL JUNCTION; OPEN-LABEL; T-CELLS; PD-1; BLOCKADE; 22C3; PHARMDX; PHASE-II; EXPRESSION; NIVOLUMAB; EFFICACY; LAG-3;

D O I：

10.1186/s40364-022-00413-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Gastric cancer is characterized by high morbidity and mortality worldwide. Early-stage gastric cancer is mainly treated with surgery, while for advanced gastric cancer, the current treatment options remain insufficient. In the 2022 NCCN Guidelines for Gastric Cancer, immunotherapy is listed as a first-line option for certain conditions. Immunotherapy for gastric cancer mainly targets the PD-1 molecule and achieves therapeutic effects by activating T cells. In addition, therapeutic strategies targeting other molecules, such as CTLA4, LAG3, Tim3, TIGIT, and OX40, have also been developed to improve the treatment efficacy of gastric cancer immunotherapy. This review summarizes the molecular biomarkers of gastric cancer immunotherapy and their clinical trials.

引用

页数：13

共 101 条

[21] PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer [J].

Evrard, Camille ;

Louvet, Christophe ;

Hajbi, Farid E. L. ;

Fiore, Frederic D., I ;

Malicot, Karine L. E. ;

Aparicio, Thomas ;

Bouche, Olivier ;

Laurent-Puig, Pierre ;

Bibeau, Frederic ;

Lecomte, Thierry ;

Lievre, Astrid ;

Guimbaud, Rosine ;

Kim, Stefano ;

Zaanan, Aziz ;

Sokol, Harry ;

Chibaudel, Benoist ;

Desrame, Jerome ;

Pierre, Sabrina ;

Gonzalez, Daniel ;

Lepage, Come ;

Tougeron, David .

DIGESTIVE AND LIVER DISEASE, 2021, 53 (04) :420-426

[22] Helicobacter Pylori Infection [J].

Fischbach, Wolfgang ;

Malfertheiner, Peter .

DEUTSCHES ARZTEBLATT INTERNATIONAL, 2018, 115 (25) :429-436

[23] Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial [J].

Fuchs, Charles S. ;

Ozguroglu, Mustafa ;

Bang, Yung-Jue ;

Di Bartolomeo, Maria ;

Mandala, Mario ;

Ryu, Min-Hee ;

Fornaro, Lorenzo ;

Olesinski, Tomasz ;

Caglevic, Christian ;

Chung, Hyun C. ;

Muro, Kei ;

Van Cutsem, Eric ;

Elme, Anneli ;

Thuss-Patience, Peter ;

Chau, Ian ;

Ohtsu, Atsushi ;

Bhagia, Pooja ;

Wang, Anran ;

Shih, Chie-Schin ;

Shitara, Kohei .

GASTRIC CANCER, 2022, 25 (01) :197-206

[24] Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial [J].

Fuchs, Charles S. ;

Tomasek, Jiri ;

Yong, Cho Jae ;

Dumitru, Filip ;

Passalacqua, Rodolfo ;

Goswami, Chanchal ;

Safran, Howard ;

dos Santos, Lucas Vieira ;

Aprile, Giuseppe ;

Ferry, David R. ;

Melichar, Bohuslav ;

Tehfe, Mustapha ;

Topuzov, Eldar ;

Zalcberg, John Raymond ;

Chau, Ian ;

Campbell, William ;

Sivanandan, Choondal ;

Pikiel, Joanna ;

Koshiji, Minori ;

Hsu, Yanzhi ;

Liepa, Astra M. ;

Gao, Ling ;

Schwartz, Jonathan D. ;

Tabernero, Josep .

LANCET, 2014, 383 (9911) :31-39

[25]

Fugazzola Paola, 2018, Acta Biomed, V89, P110, DOI 10.23750/abm.v89i8-S.7897

[26] Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603) [J].

Fukuoka, Shota ;

Hara, Hiroki ;

Takahashi, Naoki ;

Kojima, Takashi ;

Kawazoe, Akihito ;

Asayama, Masako ;

Yoshii, Takako ;

Kotani, Daisuke ;

Tamura, Hitomi ;

Mikamoto, Yuichi ;

Hirano, Nami ;

Wakabayashi, Masashi ;

Nomura, Shogo ;

Sato, Akihiro ;

Kuwata, Takeshi ;

Togashi, Yosuke ;

Nishikawa, Hiroyoshi ;

Shitara, Kohei .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (18) :2053-+

[27] Understanding the CD28/CTLA-4 (CD152) Pathway and Its Implications for Costimulatory Blockade [J].

Gardner, D. ;

Jeffery, L. E. ;

Sansom, D. M. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (09) :1985-1991

[28] Enhanced suppressor function of TIM-3+FoxP3+ regulatory T cells [J].

Gautron, Anne-Sophie ;

Dominguez-Villar, Margarita ;

de Marcken, Marine ;

Hafler, David A. .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2014, 44 (09) :2703-2711

[29] T-CELL ACTIVATION - 2-FOR-T [J].

GUERDER, S ;

FLAVELL, RA .

CURRENT BIOLOGY, 1995, 5 (08) :866-868

[30] The Tumor Microenvironment Innately Modulates Cancer Progression [J].

Hinshaw, Dominique C. ;

Shevde, Lalita A. .

CANCER RESEARCH, 2019, 79 (18) :4557-4566

← 1 2 3 4 5 6 7 8 9 10 →